Menu

John Wilkinson

Partner

It is great to be able to put my technical background into assisting clients with developing their businesses.

jwilkinson@cooley.com

John Wilkinson's practice focuses primarily on the life sciences sector, advising pharmaceutical, biotechnology and medical technology companies on a wide range of IP, regulatory, antitrust and transactional matters. Amongst other things, John's practice has involved a number of highly complex alliances and joint ventures, co-promotional and co-marketing arrangements, distribution and supply agreements, together with the operational, IP, antitrust and regulatory issues relating to such transactions.

Download full bio 

Experience

  • Bavarian Nordic Acquires Emergent BioSolutions’ Travel Vaccines Portfolio 

  • Bavarian Nordic Acquires Two Commercial Vaccines from GlaxoSmithKline for €796 Million 

  • Silence Therapeutics Enters Collaboration With Mallinckrodt Worth up to $2 Billion 

  • Jazz Pharmaceuticals Acquisition of Redx Pharma's pan-RAF Inhibitor Program Valued up to $206 Million 

  • Mission Therapeutics Enters Collaboration Agreement with AbbVie 

  • View all

"He is one of the pioneers of the biotech industry and is doing cutting-edge work." – Chambers & Partners, 2020
Education

  • College of Law, Chester
    MAC, Law Society Finals
    1993

  • Imperial College London
    BS, Chemistry
    1986

Rankings & Accolades

    Legal 500 UK: Life Sciences and Healthcare (2022)

    Chambers & Partners UK: Transactional Life Sciences

    The Legal 500 UK: Transactional Life Sciences

    PLC Global Counsel: Transactional Life Sciences

    IAM's Guide to the World's Leading Patent & Technology Licensing Lawyers

    IAM Patent 1000

    IAM Strategy 300

    Who's Who Legal Life Sciences: Transactional - Global Leader (2020) and Transactional Life Sciences Lawyer of the Year (2016)

    The Times: Lawyer of the Week